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Abstract
Both the proper functioning of the female reproductive tract (FRT) and normal placental development are essential for
women’s health, wellbeing, and pregnancy outcome. The study of the FRT in humans has been challenging due to
limitations in the in vitro and in vivo tools available. Recent developments in 3D organoid technology that model the
different regions of the FRT include organoids of the ovaries, fallopian tubes, endometrium and cervix, as well as placental
trophoblast. These models are opening up new avenues to investigate the normal biology and pathology of the FRT. In this
review, we discuss the advances, potential, and limitations of organoid cultures of the human FRT.
Facts
● The efficient and coordinated function of the FRT is
essential for reproduction and women’s wellbeing.
Perturbations in these processes are the cause of a range
of disorders from infertility to cancer.
● Organoids can be derived from healthy and pathological
tissues of the FRT.
● Organoids of the reproductive tract faithfully recapitu-
late key morphological, functional, and molecular
characteristics of their cells of origin.
● The organoid systems provide an essential tool to study
the physiology and disease of the FRT.
Open questions
● How well do FRT organoids model the cellular
heterogeneity of the tissue of origin?
● Are the different cell states across the menstrual cycle
represented in the FRT organoid models?
● What are the signaling pathways and transcriptional
networks regulating proliferation and differentiation of
the organoids of the FRT?
● Can FRT organoids be used to generate more complex
models that incorporate stromal and immune cell types?
● Can early developmental processes of pregnancy be
modeled by co-culture of FRT organoids with embryos
or trophoblast organoids?
Introduction
The female reproductive tract (FRT) develops during fetal
and early postnatal life [1]. It is derived principally from the
Müllerian ducts (also referred to as the paramesonephric
ducts) that develop from the intermediate mesoderm of the
urogenital ridge on either side of the midline during 6–9.5
gestational weeks in humans [2]. Initially, this structure is
present in both sexes, but the secretion of anti-Müllerian
hormone results in regression of the Müllerian ducts in
males [3]. In contrast, in females, they differentiate to
develop into the fallopian tubes, uterus, cervix, and upper
vagina. The ovaries are derived from the genital ridge which
forms on the medial side of the urogenital ridge. The proper
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development and functioning of the FRT are essential for it
to fulfill its ultimate goal of reproduction that includes the
physiological processes of oocyte maturation, fertilization,
implantation, fetal growth, and parturition.
Disorders of FRT that include carcinomas of the cervix
and endometrium, endometriosis, infertility, and heavy
menstrual bleeding are alarmingly common and are a source
of major suffering [4]. Effective treatments are still lacking
for many of these conditions. Furthermore, factors such as
obesity and delaying the age of reproduction have led to an
increase in prevalence in infertility and uterine cancers
[5, 6]. Thus, understanding the biology of the FRT is
becoming of increasing importance.
Neither the biology of the normal human FRT nor the
etiology of most of its disorders is clearly understood
because they have been difficult to study ex vivo. The most
commonly used in vitro models include primary cells,
cancer cell lines, tissue explants, and organotypic cultures
[7–59] (Table 1). However, they have limitations. Primary
cells from tissue biopsies cannot be propagated indefinitely
and lose their epithelial phenotype. Available cell lines are
often derived from cancers or are immortalized and do not
Table 1 In vitro models of the
human FRT used before the
establishment of
organoid systems.
Cell culture system Tissue Model Referencea
2D Ovaries Tissue-derived ovarian surface epithelial cultures [7–9]
Immortalized ovarian surface epithelial cultures [10–12]
Fallopian tubes Tissue-derived epithelial cultures [13]
Immortalized epithelial cultures [14–16]
Endometrium Tissue-derived epithelial cultures [17–19]
Tissue-derived stromal cultures [18, 20]
Tissue-derived endothelial cultures [21–23]
iPSC-derived stromal cultures [24]
Carcinoma-derived cell lines (HEC-1, Ishikawa,
RL95–2, St-1b, ECC-1)
[25–29]
Cervix Tissue-derived epithelial cultures [30–32, 34, 35]
HPV16-immortalized epithelial cell line [36]
Carcinoma-derived cell lines (HeLa,SiHa,C33a,
CaSki,ME-180)
[33, 37]
3D Ovaries Tissue-derived epithelial spheroid cultures [38, 39]
Fallopian tubes Tissue-derived epithelial spheroid cultures [40]
iPSC-derived epithelial cell 3D cultures [41]
Endometrium Tissue-derived epithelial cell 3D cultures [42]
Organotypic cultures from endometrial tissue [43–46]
Mesenchymal-derived epithelial-like cell 3D
cultures
[47]
Spheroids derived from endometrial
adenocarcinoma cell lines
[48]
Spheroids of mesenchymal stem cells derived
from menstrual blood/endometrial fragments
[49]
Cervix Organotypic cultures from primary cervical
epithelial cells
[50, 51]
Organotypic cultures from HPV16-
immortalized cells
[50]
Tissue explants Ovaries Ovarian tissue explants [52]
Fallopian tubes Fimbria explants [53, 54]
Endometrium Non-pregnant endometrium explants [55, 56]
1st trimester decidua parietalis explants [57, 58]
Cervix Cervical explants [59]
A summary of the different in vitro tools available for studying the biology of human FRT (excluding the
recently derived organoid models). The models have been grouped according to the culture type: 2D
monolayer cultures, 3D models and tissue explants. A few representative references are cited per type
of model.
aReprentative references of each model.
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represent cells in their normal physiological state. Although
cell lines derived from endometrial (e.g., Ishikawa, ECC-1)
[26, 60], cervical (e.g. HeLa [30], SiHa [31], C33a [32]),
and ovarian carcinomas [7, 61, 62] have been essential tools
to study these tumors, they do not maintain the original
cellular heterogeneity due to selection of cells with pro-
liferative advantage. Furthermore, culturing cells in two-
dimensional (2D) monolayers deprives them of the three-
dimensional (3D) environmental stimuli from the sur-
rounding matrix that play a major role in cellular behavior
[63]. The study of the physiology of pregnancy in humans
has also been a major challenge because, compared with
other organs, the reproductive tract and its association with
the placenta are the most evolutionary diverse across spe-
cies. Many of the human-specific features are modeled only
to a limited extent in animal models and available in vitro
tools. Thus, long-term physiologically relevant models that
recapitulate epithelial architecture, cellular heterogeneity
and functionality of the different regions of the human FRT
are essential.
Culturing cells in 3D is a technique that has been
employed for decades using a variety of methods, but these
were not chemically defined nor standardized (Table 1). In
2009, Sato and Clevers described a 3D culture system that
has led to the systematic generation of organoids from many
different organs [64]. Organoids are 3D cellular structures
that retain functional and morphological features of tissues
[65]. They can be derived from tissues or pluripotent stem
cells. For the generation of organoids from tissues, primary
cells are embedded into a hydrogel containing extracellular
proteins, usually the commercially available Matrigel iso-
lated from Engelbreth-Holm-Swarm (EHS) mouse sarcoma,
which acts as its basement membrane. Cells are cultured in
a medium that recapitulates signals from the specific niche
for each tissue. The organoid technology has several major
advantages: long-term propagation of primary cells; reca-
pitulation of the molecular, and functional characteristics of
the tissue; genetic stability over time; freezing/thawing
allowing bio-banking; and the ability to manipulate
experimentally with a range of approaches [65]. Organoid
technology is now transforming the way we study the FRT
in physiology and disease.
Here, we provide a general overview of the female
reproductive system and describe the organoid models
available to study its biology in health (including preg-
nancy) and disease (Fig. 1). We focus on organoids derived
from human adult tissues. We include trophoblast organoids
as, although the placenta is an organ of fetal origin and is
not part of the FRT, it is closely associated as a functional
unit with the uterine lining, the decidua, during pregnancy.
Organoids for the study of tissue physiology
of the FRT and placenta
Ovaries
The ovaries are responsible for the cyclical maturation and
release of oocytes into the fallopian tubes. They also
function as endocrine glands, secreting estrogen and pro-
gesterone, that act together to coordinate the cyclical
changes in the endometrium [66]. In mammals, the ovaries
are attached to the uterus by the ovarian ligaments. Like
other organs of the reproductive tract, the ovaries are
dynamic as demonstrated by the cyclic rupture and repair of
the ovarian surface epithelium (OSE) [67]. Under the
Fig. 1 Tissue-derived organoids of the human FRT and placenta. a
Types of organoids derived from the human FRT using tissue samples
(normal and pathological) from non-pregnant women: ovaries, fallo-
pian tubes, endometrium, and cervix. Organoids can also be derived
from disorders of the FRT such as endometriosis and cancer. The
different organoid systems show specific features that recapitulate the
epithelial organization of their tissue of origin. b Organoid systems
that have been derived from the pregnant endometrial lining (decidua)
and the first-trimester placenta (fetal origin).
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influence of pituitary gonadotropins (follicle-stimulating
hormone and luteinizing hormone), the ovarian follicles
grow and ultimately the oocyte is released from the ruptured
OSE at ovulation. The released oocyte is collected by cili-
ated cells in the fimbria of the fallopian tubes (Fig. 2). Post
ovulation, the OSE proliferates in order to efficiently repair
the wound [67].
No long-term cultures of the healthy ovarian epithelium
have yet been reported. The first 3D cultures of OSE were
established to investigate the link between chronic inflam-
mation and ovarian cancer [68]. Tissue-derived cultures of
OSE from women with benign gynecological diseases were
seeded on Matrigel-coated wells overlayed with 2%
Matrigel in a medium based on 3D cultures of mammary
epithelial acini. Single cell-layered epithelial spheroids
formed that were surrounded by a basement membrane,
containing a central lumen. The spheroids showed apical
polarity but failed to grow long-term. Continuous treatment
of the spheroids with TNFα induced a precancerous phe-
notype with increased proliferation and loss of apicobasal
polarity. More recently, 3D cultures from OSE have been
derived from carriers at high risk of ovarian cancer due to
BRCA1/BRCA2 mutations, who had undergone prophylactic
bilateral salpingo-oophorectomy (Tables 2 and 3). The
organoids are of epithelial origin (KRT8+) and have a cystic
morphology with epithelial invaginations. Although they
express the proliferative marker Ki67, their growth is slow
with cultures becoming confluent after 2–3 weeks [69].
Fallopian tube
Fallopian tubes are bilateral ducts that connect the uterine
body to the ovaries. In humans, fallopian tubes consist of
four segments: the fimbriated ends bordering the ovaries
(infundibulum), the ampulla, the ampulla–isthmus junction,
and the isthmus (Fig. 2). There are characteristic folds in the
epithelium along the entire length of the fallopian tubes.
The fallopian tubal epithelium contains secretory (PAX8+,
OVGP1+) and ciliated columnar (FOXJ1+, TUBB4A+)
cells. The highest number of ciliated cells is in the fimbriae
(up to 80%), decreasing to 30% in the isthmus [70]. These
cilia capture the oocyte when it is released at ovulation and
guide it down into the ampullary–isthmus junction for fer-
tilization by sperm and then continue to guide the zygote
into the uterus. The secretions from the secretory cells
contribute by enhancing oocyte/zygote motility [70].
The first tissue-derived organoids of the FRT were from
human fallopian tubes [71]. Cell isolates were prepared by
enzymatic digestion and these were grown as monolayers
until 70% confluence and then embedded into Matrigel
(Table 2). The organoids recapitulate the in vivo phenotype
functionally and phenotypically as demonstrated by their
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and by the presence of cilia, secretions, and folding of
epithelium. They can be stably expanded long-term and are
bipotent, giving rise to both secretory (PAX8+) and ciliated
(TUBB4A+) cells. Active WNT and NOTCH signaling are
required for the maintenance of the stem cells (Table 3). On
the other hand, inhibition of NOTCH signaling leads to a
decrease in Ki67+ proliferative cells with an increase in
ciliated cells and upregulation of genes involved in cilio-
genesis, ARMC4, DNAI1, FOXJ1, and LRRC6 [71].
Endometrium
The endometrium, the mucosal lining of the uterus, is
essential for reproduction in mammals and defects in its
function are associated with implantation failure and preg-
nancy disorders [72, 73]. In humans, it is organized into the
functional layer facing the uterine cavity and the underlying
basal layer, which is adjacent to the myometrium (Fig. 3a).
The functional layer is covered by a luminal epithelium
from which the glandular epithelium invaginates into the
stroma reaching as far as the basal layer. Whilst the luminal
epithelium provides the site of implantation for the embryo,
the glandular secretions support the development of the
conceptus during the early weeks of pregnancy [74, 75].
The endometrium is highly dynamic and its regeneration,
growth, and differentiation are exquisitely controlled by
cyclical changes of ovarian hormones (Fig. 3a). The
beginning of the cycle is marked by menstruation, during
Table 3 Medium components for the culture of organoids derived from the human FRT and placenta.
Type Expansion medium componentsa Differentiation medium components Reference
Ovarian Wnt CM, RSPO1 CM, Noggin, Nicotinamide, EGF, A83-01,
Heregulinβ-1, Y-27632, Forskolin, Hydrocortisone, β-Estradiol
– [69]
Fallopian Tube Wnt3A CM, RSPO1 CM, Noggin, Nicotinamide, EGF, FGF10, Y-
27632, SB431542
β-estradiol, progesterone [71]
Endometrial RSPO1, Noggin, Nicotinamide, EGF, FGF10, HGF, A83-01 β-estradiol, progesterone, cAMP, PRL, hPL, HCG [78]
Wnt3A CM, RSPO1 CM, Noggin, Nicotinamide, EGF, FGF10,
A83-01, Y-27632, SB202190, ITS, β-Estradiol
β-estradiol, progesterone [77]
RSPO1, Noggin, EGF, A83-01, CHIR99021, PGE2 β-estradiol [79]
Cervical Endocervix: Wnt3A CM, RSPO1 CM, Noggin, Nicotinamide,
EGF, FGF10, SB431542, Y-27632
– [94]
Ectocervix: Noggin, Nicotinamide, EGF, FGF10, SB431542, Y-
27632, Forskolin, Hydrocortisone
Trophoblast RSPO1, Noggin, EGF, HGF, A83-01, CHIR99021, PGE2 Withdrawal of RSPO1 and CHIR99021 [100]
RSPO1, Noggin, EGF, HGF, FGF2, A83-01, CHIR99021, Y-
27632, PGE2
Adapted from Okae 2018: 2-mercaptoethanol, BSA, ITS-X supplement,
NRG1, A83-01, KOSR; after cell outgrowth (d7-10) NRG1 was omitted
[101]
The medium composition for culturing organoid models of normal FRT tissue and placenta are listed. The growth factors and inhibitors are shown
and the basal medium components (e.g., DMEM/F12, N2, B27, N-acetyl cysteine, Hepes, antibiotics) are not listed.
RSPO1 R-spondin 1, EGF epidermal growth factor, FGF fibroblast growth factor, HGF hepatocyte growth factor, ITS insulin transferrin selenium,
A83-01 TGFβ receptor inhibitor, SB431542 TGFβ receptor inhibitor, SB202190 p38 MAPK inhibitor, Y-27632 ROCK signaling inhibitor,
CHIR99021 GSK-3 inhibitor, PGE2 prostaglandin E2, cAMP 8-Bromoadenosine 3’5’-cyclic monophosphate, PRL Prolactin, hPL human Placental
Lactogen, HCG Human Chorionic Gonadotropin, NRG1 Neuregulin 1, KOSR Knockout Serum Replacement, BSA Bovine Serum Albumin, CM
conditioned medium.
aExcluding basal medium components.
Fig. 2 Anatomical relationship of the ovary and the fallopian tube
at the time of ovulation. The fallopian tubes consist of: the fimbriae,
projections bordering the ovaries; the infundibulum, opening to which
fimbriae are attached; the ampulla, the longer section of the tube where
fertilization usually occurs; the isthmus, narrow section adjacent to the
uterine cavity and the interstitium that extends from the uterine cavity
through the uterine muscle (central box). The ovaries are encapsulated
by the single-cell layered ovarian surface epithelium (OSE). The
fimbria of the fallopian tube envelops the ovaries and consists of the
columnar ciliated and secretory epithelium. During ovulation, the OSE
ruptures resulting in the release of follicular fluid and the oocyte into
the fimbria. The oocyte will travel down the fallopian tube guided by
the movement of the cilia where it will be fertilized by a sperm cell
(right box).
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which the entire functional layer is shed. This is followed by
the proliferative phase of the cycle dominated by estrogen
from the ovarian follicle that stimulates the regeneration and
growth of the functional layer. A peak of luteinizing hor-
mone from the pituitary gland stimulates ovulation and
progesterone production by the corpus luteum during the
secretory phase. This drives a complex cascade of events
leading to decidualization, the essential process to prepare
the endometrium for pregnancy. In the absence of implan-
tation, progesterone levels drop, resulting in menstruation,
to start the cycle again [76].
Initial approaches to generate a 3D model of the endo-
metrium consisted of isolating primary cells, growing them
as a monolayer and transferring them into Matrigel to obtain
spheroidal structures with columnar epithelium [42]. There
have been several other reports but the expandability and
molecular and functional characterization of the spheroids
have not been investigated in detail [44–46]. Human and
murine organoids of endometrial epithelial cells [77, 78]
have now been generated and can be cultured long-term.
These organoids are obtained by enzymatic digestion of
endometrial tissues to release glandular fragments that are
then embedded into Matrigel droplets (Table 2). Endo-
metrial organoids are propagated in a medium that contains
activators of WNT signaling (RSPO1, WNT3A, and
CHIR99021) and growth factors (EGF, HGF, and FGF10)
to promote proliferation. Inhibitors of TGFβ and BMP
signaling pathways (A83-01 and Noggin, respectively) are
added to prevent differentiation, as well as nicotinamide for
the establishment of organoids [77–79] (Table 3). The
addition of an inhibitor of p38 MAPK together with low
levels of 17β-estradiol has also been reported [77]. Endo-
metrial organoids are spheroidal with a central lumen sur-
rounded by a single epithelial layer. They have cellular
heterogeneity, self-organize, are chromosomally stable,
have clonogenic capacity and similar molecular signatures
to the glands in vivo as shown by the expression of
glandular markers (MUC1, ECAD, KRT7, EPCAM,





endometrium is organized into
two layers, the functional layer
adjacent to the uterine lumen
and the basal layer adjacent to
the myometrium. It undergoes
cyclical growth, differentiation,
and shedding under the
influence of ovarian hormones,
estrogen (E2) (red line), and
progesterone (P4) (blue line).
The menstrual phase is followed
by an E2 dominated proliferative
phase. Ovulation marks the start
of the secretory phase during the
decidualization of the
endometrium. In the absence of
implantation hormone levels
drop, resulting in shedding of
the functional layer. The
different cell types are depicted
in the box. b
Immunofluorescence of
endometrial tissue (in vivo) and
organoids (in vitro) to visualize
proliferative (Ki67 positive,
red), ciliated (acetylated-a-
tubulin positive, red), and
secretory cells (PAEP positive,
red). Nuclei are counterstained
with Dapi (blue). White
arrowheads indicate ciliated
cells. Scale bars, 100 μm
(in vivo), 50 μm (in vitro). LE
luminal epithelium, GL glands.
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FOXA2, and Pan-KRT) [77, 78]. Endometrial organoids
can be robustly established with high success rates from
proliferative, secretory, menopausal, and pregnant endo-
metrium (decidua) [78].
Endometrial organoids recapitulate the morphology and
functions of the human endometrium in vivo by responding
to estrogen and progesterone (Fig. 3b). Treatment with
estrogen increases the number of Ki67+ cells, a marker of
the proliferative phase [77] and stimulates the generation of
ciliated cells [79]. Combined estrogen and progesterone
treatment results in nuclear expression of their receptors,
ESR1 and PGR, and production of characteristic secretory
phase proteins, progestagen-associated endometrial protein
(PAEP) and secreted phosphoprotein 1 (SPP1). Additional
treatment with signals from decidualized stroma (prolactin
and cyclic AMP) and the placenta (chorionic gonadotropin
and placental lactogen) further stimulates them to acquire a
phenotype typical of decidual glands [78].
The clonogenic ability of endometrial organoids provides
an opportunity to explore putative markers of human
endometrial stem cells [80]. CDH2, a component of the
WNT signaling pathway, is proposed as a marker of the
sparse endometrial progenitor cells thought to be located in
glands in the basal layer, and CDH2+ cells demonstrated a
higher clonogenic and proliferative capacity [81]. Single-
cell RNA sequencing of endometrial organoids revealed
proliferating, secretory, ciliated, and putative stem cell
populations [82]. The bipotential ability of the organoids
also allows the study of the epithelial differentiation pro-
cess. Similarly to the organoids from the fallopian tube,
inhibition of NOTCH signaling is involved in ciliogenesis
that is dependent on the presence of estrogen [79]. As an
example of how the organoids can be used to study endo-
metrial physiology, the role of the mechanosensitive ion
channel PIEZO1 was investigated and shown to be involved
in the establishment of a dialogue at the maternal–fetal
interface that could act as a potential target for promoting
successful implantation [83].
Cervix
The cervix connects the uterus to the upper vagina. The
increase in estrogen at ovulation causes softening and pro-
duction of cervical fluid allowing smooth transit of sperm
[84]. The cervix is divided into three regions: the ectocervix,
squamocolumnar junction (SCJ), and endocervix (Fig. 4).
The ectocervix is the outer part of the cervix that protrudes
into the vagina and has a stratified non-keratinizing squa-
mous epithelium composed of basal, parabasal, intermediate,
and superficial layers. These layers can be distinguished by
expression of specific keratins: superficial and intermediate
layers are KRT4+ and KRT13+; parabasal layers are
KRT13+, KRT14+, and occasionally KRT10+; and basal
layer express KRT5, 14, 18, and 19 [85, 86]. The endo-
cervix, which is continuous with the endometrium, has a
monolayer of mucin-producing, columnar epithelial cells
that express KRT7, 8, and 18, interspersed with sporadic
ciliated cells [87, 88].
The SCJ is a unique site because it is the junction
between two different epithelial types. It is formed
~20–24 week fetal stage in response to maternal hormones
[89], and undergoes continuous remodeling during puberty,
pregnancy, and menopause by a process of squamous
metaplasia [90], creating an area of transition between the
two epithelial lineages called the transformation zone (TZ)
(Fig. 4). Metaplastic change starts with the active division
of subcolumnar KRT17+ (reserve) cells located in the
endocervix. Subsequently, the reserve cells differentiate
Fig. 4 The anatomy of the
human cervix. The cervix
consists of two distinct epithelia;
the columnar epithelium of the
endocervix and stratified
epithelium of the ectocervix,
which merge in the
squamocolumnar junction (SCJ).
The reserve cells (in green) are
localized under the columnar
epithelium and are believed to
regulate the process of
metaplasia, which results in the
formation of a new stratified
epithelium, producing the
transformation zone (TZ).
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into layers of immature, stratified epithelium, where both
squamous and columnar components can be detected; these
progressively mature to blend with the original ectocervix,
making up the TZ [91–93].
The term ‘cervical organoids’ describes both endo- and
ecto-cervical organoids. Organoids have been generated and
cultured long-term from normal adult cervical tissues that
recapitulate the site-specific epithelial architecture of the
cervix [94] (Table 2). Differentiation towards the endo-
cervical lineage requires WNT signaling, whilst its inhibi-
tion is critical for stratification [94] (Table 3). Furthermore,
NOTCH signaling was key for squamous lineage differ-
entiation at the SCJ. The endocervical organoids express
KRT7, whilst the ectocervical ones are positive for basal
markers KRT5 and TP63. Organoids have also been derived
from the cervical SCJ and grown in a medium containing
EGF, RSPO1, Noggin, Y-27632, and Jagged-1 [95]. MMP7
and AGR2 are expressed in these organoids, which are also
KRT17+. Dual cell populations are present; endocervix/
columnar cells, which are PAS+, P40− and an ectocervix/
squamous cells which are PAS−, P40+. The percentage of
each type was variable. Further work must be carried out to
generate a more robust SCJ organoid model.
Placenta
The placenta is an extra-embryonic organ responsible for
nourishing and protecting the developing conceptus during
its life in utero. Its development begins when the blastocyst
(preimplantation embryo) segregates into the inner cell
mass and the trophectoderm. The trophectoderm comes into
direct contact with the luminal epithelium of the endome-
trium at implantation and gives rise to all the trophoblast
lineages of the placenta: an inner villous cytotrophoblast
(VCT) and an outer syncytiotrophoblast (SCT) responsible
for maternal–fetal exchange and production of pregnancy
hormones and the extravillous trophoblast (EVT) which
migrate out of the villi and attach and invade into the
decidua, the pregnant endometrium [96] (Fig. 5a). In
humans, the placenta is intimately associated with the
decidua. The EVT transforms the spiral arteries from out-
side via the stroma (interstitial invasion) and inside (endo-
vascular invasion). This arterial transformation is essential
to supply all the nutrients and blood to the developing fetus.
It is fundamental for the success of the pregnancy as the
major pregnancy disorders show defects in this process. The
development of the placenta is directed by signals from the
decidua including glandular secretions, which provide the
initial source of nutrition before the onset of maternal–fetal
circulation into the intervillous space [97].
Although animal models and cell lines have been
essential tools in placental research, they have several
limitations. The deep invasion of trophoblast in human
placentation is only seen in the great apes and is not fully
modeled in mice [98]. Primary human trophoblast cells
cannot be cultured long term and choriocarcinoma cell lines
have an abnormal karyotype [96]. Human trophoblast stem
cell (hTSC) lines were recently generated from blastocysts
Fig. 5 The pregnant uterus of the first trimester and the placenta.
a The placenta is firmly embedded into the pregnant lining of the
uterus, the decidua, on one side and on the other, is connected to the
fetus via the umbilical cord. b The placenta is made up of a system of
branching villi that is covered by a bilayered epithelium—a multi-
nucleated outer layer called the syncytium (SCT) and the mononuclear
epithelium, the villous cytotrophoblast (VCT). The mesenchymal core
(MC) of the villi contains stromal and endothelial cells and
macrophages. At the tips of the villi, extravillous trophoblast (EVT)
attach and invade into the stroma and the spiral arteries of the decidua.
c Trophoblast organoids derived from human first-trimester placenta.
Immunofluorescence of a placental villus (in vivo) and trophoblast
organoids (in vitro) for VCT marker EPCAM (in red). VCT is
shown with white arrows. Nuclei are stained with Dapi (blue). Scale
bars, 50 μm.
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and first trimester placentas [99]. hTSC are maintained by
activated WNT and MAPK signaling (via EGF) and inhi-
bition of TGFβ, ROCK and histone deacetylase. These cells
have clonal ability, differentiate into the two main tropho-
blast lineages, SCT and EVT, and satisfy the key criteria of
human trophoblast in vivo, providing definitive evidence
that they are indeed trophoblast. However, hTSC grow as a
monolayer and lack the architectural organization of the
placenta. To model the placental villi, trophoblast organoids
were established from first-trimester placentas (Table 2)
[100, 101]. Under conditions that promote WNT signaling,
trophoblast organoids grow with an inner syncytial mass
and an outer proliferative VCT (Fig. 5b). Switching the
medium, by either omitting WNT activators or using dif-
ferentiation medium used for 2D hTSC [99], trophoblast
organoids can be stimulated to generate EVT (Table 3).
They are genetically stable long-term and their tran-
scriptomes and epigenetic signatures closely resemble first-
trimester trophoblast in vivo. Importantly, trophoblast
organoids showed key functions of the placenta: their
secretome was investigated by mass spectrometry and many
placental products are identified and the EVT are highly
invasive and burrow their way through Matrigel [101].
These organoids provide an experimental model to inves-
tigate placental development and the cell lineage relation-
ships of the different trophoblast subpopulations. They also
provide the opportunity to study the cellular and signaling
interactions between the placenta and the decidua.
Organoids for the study of disorders of the
FRT
Endometriosis and endometrial hyperplasia
Organoids can be established from pathological samples and
provide powerful tools to study diseases ex vivo although the
culture conditions often need optimizing [69, 78, 95, 102–111]
(Table 4). A common benign condition is endometriosis where
ectopic foci of the endometrium containing both glands and
stroma are found in the peritoneal cavity, ovary, and cervix.
Active WNT and EGF, with inhibition of BMP signaling, are
necessary for efficient growth of organoids from these lesions.
Organoids from ectopic sites of endometriosis express genes
linked to stemness (SOX9, LGR6) and metalloproteinase
function (MMP2), and show luminal invasion, a common
characteristic of endometriosis. Somatic mutations in genes
associated with endometrial carcinoma (CTCF, EP300,
ZNF471) were found in organoids from late-stage endome-
triotic lesions. When engrafted into mice, they give rise to
ESR1+ and PR+ lesions. Using the same medium composition
for endometriosis, organoids can also be established from
endometrial hyperplasia. This is a condition usually found in
anovulatory women exposed to estrogen without progesterone
and is characterised by an abnormally thick endome-
trium. Organoids from endometrial hyperplasia display high
proliferative capacity and similar molecular characteristics as
the primary tissue, including absence of TP53 expression.
Mutations in mismatch DNA repair genes (MSH2, MSH6)
were observed in organoids derived from women with Lynch
syndrome [108].
Carcinomas of the FRT
Several organoid models have now been derived from
carcinomas arising in the FRT (Table 4). Ovarian carcino-
mas are heterogeneous with high grade serous ovarian
carcinoma (HGSOC) being the deadliest and most common
type [112]. It seems that HGSOC originates from the epi-
thelium of the fimbriae of the fallopian tube [113], although
others have proposed the source is the OSE [114]. 3D
cultures from solid tumors, ascitic, and pleural fluid of
patients with ovarian carcinoma were generated [103].
Whilst these cultures displayed clonogenic capacity and
morphological and molecular similarity to the primary
tumors, they could only be expanded short-term. In another
study, a biobank of organoids from pre-malignant and
malignant ovarian neoplasms was established [69]. These
organoids recapitulate morphological (nuclear and cellular
atypia), phenotypic (PAX8+, TP53+), and genomic features
(mutations in KRAS, BRAF, cell cycle genes, and TP53),
capture tumor heterogeneity and can be expanded long-
term. However, these culture conditions are still suboptimal
and HGSOC organoids grow slowly. Growth and long-term
expansion has now been achieved by using media with low
WNT and active BMP signaling to maintain stem cells in
the cultures (Table 4) [106]. These conditions are also
required for the stable growth of another model of HGSOC
that were derived by the stable triple knockdown of TP53,
PTEN, and RB in fallopian tube organoids [106].
Similarly, organoids can be derived from different
stages of endometrial neoplasms that capture the phe-
notypic and genetic heterogeneity (Table 4). Low WNT
but high p38 MAPK signaling, both associated with cell
proliferation and differentiation, together with high
concentration of β-estradiol, addition of growth factors
(IGF1, HGF) and lipids enhance the expandability of
organoids derived from endometrial carcinomas [108].
Organoids from low-grade endometrial carcinomas bear
mutations in tumor suppressor genes (PTEN, CTCF, and
ARID1A) and the β-catenin coding gene (CTNNB1),
resulting in continuous activation of the WNT pathway.
In contrast, organoids from high-grade endometrial car-
cinomas were characterized by downregulation of
glandular markers (ESR1, FOXA2) but upregulation of
EMT-associated genes (CXCR4, TWIST1, ZEB1, and
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CDH2) [108]. These organoids can be orthotopically
engrafted into murine uterine horns where the histolo-
gical and molecular features of the original lesion are
retained with the potential to metastasize [108].
Organoids derived from clear cell carcinoma, a rare
tumor of the cervix could be propagated for more than
6 months, retained 2 out of 3 mutations (MLH1 and TFE3)
detected in the original tumor and typical markers, HNF1‐β,
TP53, and Ki‐67 [115] (Table 4). Their appearance was
similar to the original tumor with atypical cells with clear
cytoplasm. No organoid models of squamous cervical car-
cinoma have been reported.
Drug screening on patient-derived organoids
Patient-derived organoids from pathologies of the FRT can be
frozen and thawed allowing generation of extensive biobanks,
which can be used for drug sensitivity screening and ulti-
mately for personalized medicine [69, 102, 104, 105, 108].
When treated with platinum/taxane, drugs commonly used for
treating ovarian cancer, different organoid lines showed dif-
ferential drug responses. Sensitive and resistant organoids
correlated with the grade of the tumor (high or low) and the
degree of chemoresistance previously noted in the patients
[69]. Drug responses have also been examined in vivo in mice
xenografted with organoids of ovarian carcinomas [69]. When
the mice were treated with gemcitabine, a nucleoside analog
commonly used for the treatment of HGSOC, proliferation,
and invasion of the tumors was restricted.
Similarly, patient-specific responses were also observed
in organoids derived from endometrial carcinoma treated
with standard chemotherapeutic compounds
[108, 110, 111]. The resistance of the organoids to cisplatin
and paclitaxel echoed the patients’ clinical response to
treatment [111]. Another report described the induction of
apoptosis in organoids from endometrial carcinoma in
response to verteporfin, a drug which inhibits the HIPPO
pathway [109]. Similarly, napabucasin, an inhibitor of
STAT3 signaling hampered their growth [110]. This
variability in drug response may be due to the lack of
stromal or immune cells in these organoid models
[116, 117], which could be resolved with the development
of co-culture systems.
Applications and future perspectives of FRT
organoids
Genome engineering
Combining techniques to engineer genomes of organoids
from the FRT open up new possibilities to study its phy-
siology and disease (Fig. 6a). There is still much to learn
about epithelial regeneration, maintenance, and differentia-
tion of the FRT and it is evident that CRISPR/Cas9 gene
editing technology will help address many outstanding
questions. It allows site-specific targeting to disrupt or
modify a genetic locus of interest. For example, transcrip-
tion factors involved in proliferation and differentiation of
the epithelial cells of the FRT can be targeted to study their
functions. It can be used for creating reporter lines and
performing lineage tracing experiments to identify pro-
genitor populations of the different regions of the FRT. In a
forward genetics approach, specific mutations can be
Fig. 6 Applications of tissue-derived organoids of the female
reproductive tract and placenta. a Organoid systems can be used for
studying the physiology and pathologies of the FRT. They can be used
as. tools for testing drug responses and drug development. Gene
function can be assesed by CRISPR/Cas9 based genetic engineering of
organoids. b The possibility to combine organoids with different cell
types as well as pathogens will allow studies on their interactions.
Bioengineering methods may allow the generation of more complex
tissue-like models that include non-epithelial populations such as
fibroblasts, immune and endothelial cells. The interactions between
two different tissues can also be studied by co-culture of organoids,
which is of particular relevance for maternal–fetal crosstalk using
placental (trophoblast) and endometrial organoids.
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introduced to study the etiology of endometrial and cervical
carcinomas as previously done for targeting genes involved
in ovarian cancer using fallopian tube organoids [69].
Assisted reproductive techniques
One of the exciting prospects of the generation of organoids
from the different regions of the FRT is the possibility of
personalized medicine (Fig. 6a). This is especially relevant
for studying infertility. Even though all patients undergoing
in vitro fertilization (IVF) have the same hormonal treat-
ment, the cause of the infertility is unexplained in ~30% of
cases [118]. Organoids could be generated from endo-
metrial biopsies from women undergoing IVF and exposed
to these hormonal regimes to investigate whether differ-
ential responses may be one of the possible causes. Treat-
ment regimens could then be tailored to each patient. A
similar approach could be used for treating endometriosis
where the eutopic endometrium is often progesterone
resistant and patients have fertility issues [119].
Further optimization of organoid models of the healthy
ovarian epithelium could prove useful in treating sub-
optimal infertility caused by anovulation that occurs in
women with polycystic ovary syndrome. Ovulation induc-
tion is one of the most common therapeutic approaches.
This comes with risks of ovarian hyperstimulation syn-
drome [120], causing patients a range of symptoms
(abdominal pain, vomiting, fluid accumulation in the
abdomen, and lungs) that may require hospitalization. In
vitro maturation of eggs, using ovarian organoids would be
a less invasive and risky approach for assisted reproductive
technology.
Co-culture models of FRT
Tissue-derived organoids of the FRT include only the epi-
thelial compartment and thus do not fully reflect the cellular
complexity of the native tissues. For the study of cellular
interactions, multicellular organoid co-culture systems are
necessary (Fig. 6b). The interdependence of endometrial
epithelial cells with stromal cells in the endometrium has
been studied extensively using animal models but this is
difficult to model in humans [121, 122]. Stromal cells
respond to estrogen and progesterone by producing pro-
lactin and IGFBP1, which act on the glands to stimulate
secretions [123]. In an organotypic approach, glandular
epithelial cells embedded in Matrigel were cultured on a
monolayer of stromal cells to investigate the effects of
steroid hormones and anticancer drugs on the epithelial
compartment [124]. Alternative methods for epithelial-
stromal co-cultures utilize scaffolds. This also cirumvents
the use of Matrigel which is not chemically defined and has
batch-to-batch variation [125]. Recently, a porous collagen-
based co-culture model of the epithelial and stromal cells of
the endometrium was developed with both cell types being
functionally responsive to hormones [126]. In future, the
architecture of these scaffolds could be manipulated to
allow the formation of gland-like structures that closely
resemble the native tissue. Careful comparison with infor-
mation about the in vivo environment is essential to prove
the validity of the models [127], and to identify the char-
acteristics of the niche that target epithelial populations
[128]. Although these systems show promise in under-
standing the endometrium as a whole, there are still issues
to resolve like finding media appropriate for all cell types.
Immune cells play a major role in the homeostasis and
function of the FRT. In the endometrium, progesterone
upregulates IL-15 that is trans-presented by stromal cells to
stimulate the proliferation and differentiation of uterine
natural killer cells [129]. How these hormonally-regulated,
distinctive, uterine lymphocytes play a role in epithelial
regulation and function has been challenging to study. Co-
culture methods that combine epithelial organoids with
immune cells provide insights into normal intestinal
homeostasis and diseases including gastric, pancreatic,
colorectal, lung, and breast neoplasms [130]. Similar co-
culture systems of organoids of FRT with immune cells will
clearly be an important advance (Fig. 6b). They will also be
important in understanding behavior of tumors of the FRT
where the microenvironment plays a crucial role in the
development and progression of the disease [131].
A further use of multicellular culture models of the FRT
would be to explore early developmental events in humans
that are impossible to study in vivo (Fig. 6b). Though such
studies need to be scrutinized appropriately and ethical
considerations must be taken into account [132]. An artifi-
cial endometrium could be used to model implantation in a
dish [133, 134]. Previous attempts to study the attachment
of the blastocyst or trophoblast onto the endometrium
[45, 46, 48, 135] used epithelial monolayers superimposed
on stromal cells, thus not recapitulating the in vivo 3D
glandular structure. An important application of trophoblast
organoids that differentiate to invading EVT, will be to
study molecular and functional interactions with decidual
cells (uterine NK, macrophages, epithelial, and stromal
cells) in vitro.
FRT organoids and infection
Organoids are a practical model to study infectious diseases
[65]. Tubal infections caused by sexually transmitted dis-
eases, misuse of intrauterine contraceptive devices, or post-
miscarriage, can lead to tubal fibrosis, loss of patency, and
infertility [136]. Such infections have also been linked to
cancer [137]. The most common pathogen is Chlamydia
trachomatis. A microarray analysis of infected organoids
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during the acute phase of a Chlamydia Ctr serovar D
infection shows prolonged activation of leukemia inhibitory
factor signaling that could play a role in maintaining stem
cell identity (Table 4) [107]. The robust activation of
paracrine networks controlling not only cell growth and
proliferation, but also differentiation and cell fate, suggests
that Ctr infection has pervasive long-term consequences on
the epithelium.
Pathogens of the lower reproductive tract including vaginal
bacterial species (lactobacilli and vaginosis associated bac-
teria) can ascend to the endometrial cavity [138]. Infection
with Neisseria gonorrhoeae of 3D epithelial cultures derived
from endometrial adenocarcinoma resulted in upregulation of
proinflammatory mediators and morphological changes to the
host cells [139]. Endometrial organoids will be a valuable
model to investigate chronic endometritis commonly caused
by Chlamydia trachomatis, Neisseria gonorrhoeae, and Tri-
chomonas vaginalis [140]. Co-culture of immune cells with
the organoids will increase understanding of the pathogenesis
of endometritis (Fig. 6b).
The major disease affecting the cervix is dysplasia and
subsequent carcinoma caused by high-risk human papil-
loma virus (HR-HPV) [90]. Modeling the normal meta-
plastic change from glandular to squamous epithelium and
the response of the epithelium to HPV infection with pro-
gression to carcinoma will provide information about the
dynamics of epithelial renewal. In addition, cervical orga-
noids can offer a system to study sexually transmitted dis-
eases (Chlamydia trachomatis, Neisseria gonorrhoeae,
Trichomonas vaginalis, and herpes simplex virus).
Conclusions
Throughout adult reproductive life, the FRT undergoes
constant remodeling under the influence of pituitary and
ovarian hormones and, if pregnancy occurs, it goes
through dramatic changes driven by placental hormones.
Disruption of all these complex, exquisitely controlled
processes results in a diverse range of pathologies that
together affect a large number of women worldwide.
Although much is known about hormonal changes
occurring in the FRT, it is mostly descriptive without
detailed molecular and cellular information. Now avail-
able are essential experimental organoid models of the
FRT that recapitulate the original tissues (healthy or
pathological). Although organoid cultures are more labor
intensive and costly compared with standard 2D culture,
they can be set-up with relative ease allowing wide-spread
use. There are still many questions to be answered
regarding the FRT organoids. Efforts are now being made
to define the common issues affecting all organoids sys-
tems such as reproducibility, standardization, and
diligence validation [141]. This is an exciting time for
reproductive research as recent progress paves the way for
opportunities to improve women’s wellbeing and repro-
ductive health.
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